Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil

University of Sao Paulo30 enrolled

Overview

Besides the specific response to vaccine antigens, the investigators will analyze the anti-HPV immune response in HIV-1-infected men in different strata of immune deficiency. The hypothesis will be tested by stratification by T CD4 + lymphocytes in an attempt to assess the range of the count with the highest possibility of vaccine response. Thus, knowledge of vaccine response in HIV-infected patients, indicate which patients would have greater potential for vaccine response in vivo.

The study will be divided into three groups. Patients with HIV-1 infection will be subdivided into groups according to T CD4 + lymphocytes at the time of vaccination: Over 500 CD4 T cells count and bellow 500 CD4 T cells count. A healthy control group will be also studied.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Infection

Interventions

HPV vaccineBIOLOGICAL

HPV vaccine

Eligibility

Sex: MALEMin age: 35 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: HIV * Men with age between 35 and 45 years of age. Exclusion Criteria: * Current or previous infection with human papillomavirus (HPV)

Locations (1)

Institute of Tropical Medicine of Sao Paulo

São Paulo, São Paulo, Brazil

Outcomes

Primary Outcomes

Presence of Anti-HPV antibody titers

The anti-HPV titers will be compared from baseline to the date of sample collection

Time frame: 0, 30 and 180 days of vaccination anti-HPV

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.